Do you switch patients living with HIV off of boosted protease inhibitor-based regimens if possible to avoid the increased cardiovascular risk associated with them?

Yes, I usually do, despite my deep respect for PIs, which turned the tide in the United States in the 1990s from a universally fatal condition into a chronic disease. Some studies, most prominently the D:A:D study, suggest that ritonavir-boosted darunavir may increase the risk of CVD; however, other...